Arbutus Biopharma Corporation announced that Dr. Frank Torti has been appointed as Chairman of the company’s Board of Directors, effective November 26, 2018. In August 2018, Dr. Torti became the Vant Investment Chair for Roivant Pharma. In that capacity he serves on the boards of Myovant Sciences, Urovant Sciences, Axovant Sciences, and other private companies in the Roivant family. Dr. Torti replaces Vivek Ramaswamy, Founder and CEO of Roivant Sciences, as Chairman of the Arbutus Board of Directors. Mr. Ramaswamy has resigned from the Arbutus Board concurrently with Dr. Torti’s appointment, to focus on strategic and operational growth at Roivant.